Takhzyro

Chemical Namelanadelumab-flyo
Dosage FormInjection (subcutaneous; 300 mg/2 mL (150 mg/mL))
Drug ClassMonoclonal antibodies
SystemSkin
CompanyDyax Corp.
Approval Year2018

Indication

  • To prevent hereditary angioedema attacks in patients ≥ 12 years of age.
Last updated on 10/27/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Takhzyro (Lanadelumab-flyo) Prescribing Information 2018Dyax Corp., Lexington, MA
Document TitleYearSource
US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema.2020The Journal of Allergy and Clinical Immunology: in Practice
The International/Canadian hereditary angioedema guideline. 2019Allergy, Asthma & Clinical Immunology